BiotechTube
Home/Pipeline/Nurr1-targeted small molecule

Nurr1-targeted small molecule

Parkinson's Disease

Phase 1Active

Key Facts

Indication
Parkinson's Disease
Phase
Phase 1
Status
Active
Company
NurrOn Pharmaceuticals

About NurrOn Pharmaceuticals

NurrOn Pharmaceuticals is a private, clinical-stage biotech focused on a novel, disease-modifying approach to treating Parkinson's disease by targeting the Nurr1 pathway. The company is advancing its pipeline with the goal of slowing or preventing disease progression, a major unmet need in PD. Operating from the biotech hub of Cambridge, MA, NurrOn represents a specialized player in the neurodegenerative disease space. Its strategy includes exploring both monotherapy and combination regimens with existing treatments.

View full company profile

Therapeutic Areas

Parkinson's DiseaseNeurodegenerative Diseases

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical
golexanoloneUmecrine CognitionPreclinical
Parkin Activator ProgramProgenraPre-clinical
Not SpecifiedAsceneuronNot Disclosed